首页> 美国卫生研究院文献>Biomarker Insights >Challenges and Current Efforts in the Development of Biomarkers for Chronic Inflammatory and Remodeling Conditions of the Lungs
【2h】

Challenges and Current Efforts in the Development of Biomarkers for Chronic Inflammatory and Remodeling Conditions of the Lungs

机译:肺部慢性炎症和重塑条件生物标志物的开发面临的挑战和当前的努力

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

This review discusses biomarkers that are being researched for their usefulness to phenotype chronic inflammatory lung diseases that cause remodeling of the lung’s architecture. The review focuses on asthma, chronic obstructive pulmonary disease (COPD), and pulmonary hypertension. Bio-markers of environmental exposure and specific classes of biomarkers (noncoding RNA, metabolism, vitamin, coagulation, and microbiome related) are also discussed. Examples of biomarkers that are in clinical use, biomarkers that are under development, and biomarkers that are still in the research phase are discussed. We chose to present examples of the research in biomarker development by diseases, because asthma, COPD, and pulmonary hypertension are distinct entities, although they clearly share processes of inflammation and remodeling.
机译:这篇评论讨论了正在研究的生物标志物对表型慢性炎症性肺疾病的有用性,这些疾病会引起肺结构的重塑。这篇综述主要针对哮喘,慢性阻塞性肺疾病(COPD)和肺动脉高压。还讨论了环境暴露的生物标志物和特定类型的生物标志物(非编码RNA,代谢,维生素,凝血和微生物组相关)。讨论了临床使用的生物标志物,正在开发的生物标志物以及仍处于研究阶段的生物标志物的例子。由于哮喘,COPD和肺动脉高压显然具有共同的炎症和重塑过程,因此我们选择通过疾病来研究生物标志物的研究实例,因为哮喘,COPD和肺动脉高压是不同的实体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号